Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma (HCC) at high risk of recurrence following surgery met primary endpoint of...
-
Xofluza is now approved in the EU for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza in children aged one year and above, and in adolescents and adultsXofluza...
-
If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin lymphomaResults from the pivotal phase...
-
With Lunsumio, people with heavily pre-treated follicular lymphoma may experience remission with a chemotherapy-free, fixed-duration treatment that can be accessed in an outpatient settingResults from...
-
Actemra is the first FDA-approved monoclonal antibody to treat COVID-19 Since the beginning of the pandemic, more than one million people hospitalised with COVID-19 have been treated with Actemra...
-
The positive CHMP opinion is based on the results of the HAVEN 6 study, which demonstrated effective bleed control and a favourable safety profile of Hemlibra in people with moderate haemophilia A...
-
Testing early for COVID-19 can help determine the proper course of treatment.This collaboration helps patients access critical resources and locate information about testing, available treatment...
-
Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that...
-
Updated data from the phase III POLARIX study continue to demonstrate a statistically significant reduction in the risk of disease worsening or death for people with previously untreated diffuse large...
-
Board of Directors Basel, 12 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that at its December meeting, the Board of Directors of Roche Holding Ltd has approved to propose the...